HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Crackdown On Anti-Aging Imports Signals "Major Enforcement Initiative"

This article was originally published in The Rose Sheet

Executive Summary

Increased scrutiny of anti-aging products entering the U.S. presages "a major enforcement initiative" against illegal cosmetic claims that will impact domestic personal-care firms, large and small, according to attorney and ex-FDAer Benjamin L. England

You may also be interested in...

Soldiering Through Scrutiny, Nu Skin Launches Growth Plan For China

Nu Skin aims to achieve “higher levels of penetration” in China by expanding its direct-selling platform to additional provinces and tripling the number of stores and sales centers it operates by 2017. Meanwhile, short-seller Citron Research directs FDA and FTC to advertising for Nu Skin’s ageLOC line, which it asserts is rife with “unsubstantiated medical claims.”

Nu Skin Unfazed By Allegations Of China Violations, Projects More Growth

Following allegations from short seller Citron Research that it operates an illegal “pyramid compensation scheme” in China, Nu Skin gives investors a peek into its business model. The firm recorded sales growth of 40% in its second quarter, driven by a 152% jump in China, and “the best is yet to come,” Nu Skin says.

FDA Cosmetic Imports “Enforcement Spike” Serves To Warn Multinationals

FDA stepped up its surveillance of cosmetic imports over the summer, subjecting those importing products to the U.S. to increased scrutiny of color additives, labeling and permitted uses.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts